Invesco Biotechnology & Genome ETF
PBE
72 hedge funds and large institutions have $54.4M invested in Invesco Biotechnology & Genome ETF in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 13 closing their positions.
21.25% more ownership
Funds ownership: 0% → 21.25% (+21%)
3% less funds holding
Funds holding: 74 → 72 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
51% less capital inflows, than outflows
Capital inflows: $3.91M | Capital outflows: $7.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.27M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$582K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$449K |
| 4 |
Oppenheimer & Co
New York
|
+$262K |
| 5 |
Global Financial Private Capital
Sarasota,
Florida
|
+$252K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.56M |
| 2 |
Virtu Financial
New York
|
-$1.36M |
| 3 |
Institute for Wealth Management
Denver,
Colorado
|
-$1.11M |
| 4 |
YHB Investment Advisors
West Hartford,
Connecticut
|
-$1M |
| 5 |
Morgan Stanley
New York
|
-$646K |
PBE Hedge Fund Activity: Q2 2018 in Review
72 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2018, worth a combined $54.4M — up 2.1% from $53.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PBE and 11 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was UBS Group, adding an estimated $1.27M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.56M sold.
- 72 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2018, down from 74 in Q1 2018.
- Funds reported $54.4M of Invesco Biotechnology & Genome ETF stock for Q2 2018, up 2.1% quarter-over-quarter.
- 11 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2018 and 13 closed out, a net change of -2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2018 was UBS Group, an estimated $1.27M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2018 was Susquehanna International Group, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2018.